MPN

Myeloproliferative neoplasms (MPNs) are rare cancers and include diseases of the blood and bone marrow. MPNs involve dysregulation at the multipotent hematopoietic stem cell (CD34). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.

Advertisement
Advertisement
Leah SherwoodMyelofibrosis | June 17, 2024
Dr. Rampal, of Memorial Sloan Kettering Cancer Center, discusses his abstract at the EHA 2024 Congress in Madrid, Spain.
View More
Patrick DalyMyelofibrosis | June 17, 2024
MPN depend on mutated JAK signaling, and targeting the mutations suppressed disease features and improved overall survival.
Patrick DalyMyelofibrosis | June 10, 2024
Pelabresib plus ruxolitinib improved spleen and symptom responses in JAKi-naïve patients with myelofibrosis.
Patrick DalyMyelofibrosis | June 7, 2024
Treatment with luspatercept improved transfusion burden and anemia across four cohorts of patients with myelofibrosis.
Leah SherwoodMyelofibrosis | May 22, 2024
Prefibrotic PMF is an MPN with distinct characteristics comprising histopathological, clinical, and biological parameters.
Prithviraj Bose, MDMyelofibrosis | May 2, 2024
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
Melissa BadamoMyelofibrosis | April 30, 2024
Momelotinib achieved higher rates of transfusion independence compared with ruxolitinib.
Melissa BadamoMyelofibrosis | April 30, 2024
Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with MF.
Melissa BadamoMyelofibrosis | April 29, 2024
Sotatercept monotherapy, and combined with ruxolitinib, is a safe and effective treatment for patients with PMF and anemia.
Blood Cancer TalksBlood Cancer Talks | April 18, 2024
Raajit Rampal, MD, PhD, and the "Blood Cancer Talks" hosts discuss the diagnosis and management of essential thrombocythemia.
Melissa BadamoMyelofibrosis | April 4, 2024
The primary endpoint was overall best response after blast-reduction therapy.
Blood Cancers Today Staff WritersMyelofibrosis | April 1, 2024
Momelotinib and ruxolitinib improved bone marrow fibrosis, but changes were not associated with improved outcomes in MF.
Melissa BadamoMyeloproliferative Neoplasms | March 29, 2024
Dr. Harrison discusses her current clinical research, building community with MPN Voice, and her journey into hematology.
Leah SherwoodMyelodysplastic Syndromes | March 28, 2024
A drug approval specific to CMML would catalyze a surge of interest in the hematology-oncology community.
Nicolaus Kröger, MDMyelofibrosis | March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
Patrick DalyMyelofibrosis | March 22, 2024
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.
Melissa BadamoMyelofibrosis | February 28, 2024
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with myelofibrosis.
Keightley AmenMyelofibrosis | February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Sanjay Patel, MDVideo Insights | January 19, 2024
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Claire Harrison, MD, FRCP, FRCPathMyelofibrosis | February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Leah SherwoodMyelofibrosis | March 4, 2024
“Among the high-risk splicing mutations, SRSF2 has the worst prognostic role,” Dr. Braish and colleagues wrote.
Michael Grunwald, MDMyeloproliferative Neoplasms | December 14, 2023
The REVEAL study identified five risk factors, including leukocytosis, duration of time with PV, and more.
Patrick DalyMyelofibrosis | March 1, 2024
The treatment led to reduced hepcidin levels when used alone or in combination with ruxolitinib.
Sangeetha Venugopal, MDMyelofibrosis | March 4, 2024
Venugopal highlights myelofibrosis research at ASH 2023.
Andrew Kuykendall, MDPolycythemia Vera | December 13, 2023
Real-world databases lent insight into how often patients with PV experience thromboembolic events.
Haifa Kathrin Al-Ali, MDMyelofibrosis | March 4, 2024
Dr. Al-Ali covers data on combined BET and JAK inhibition for patients with myelofibrosis presented at the 2023 ASH Meeting.
Benjamin Rolles, MDMyeloproliferative Neoplasms | December 13, 2023
Worse survival in single-hit TP53 patients was mainly driven by bone marrow fibrosis.
Melissa BadamoMyelofibrosis | December 11, 2023
SRSF2 and SF3B1 were the most common splicing mutations, followed by U2AF1 and ZRSR2.
Emily HayesPolycythemia Vera | December 11, 2023
Knowing who is at high risk in the near term could make it easier to conduct trials of anti-thrombotic therapies.
Emily HayesPolycythemia Vera | December 13, 2023
Developed by Protagonist Therapeutics, rusfertide is a novel injectable synthetic mimetic of the natural hormone hepcidin.
Nico Gagelmann, MDMyelofibrosis | March 4, 2024
CALR and MPL mutations, which are associated with better outcomes, showed earlier mutation clearance than JAK2.
Blood Cancers Today Staff WritersPolycythemia Vera | February 2, 2024
The retrospective study used data on 105 million U.S. patients with linked medical and prescription claims from 2007 to 2019.
Emily HayesMyelofibrosis | March 4, 2024
Mass spectrometry–based proteomics were used to learn more about how MKs drive bone marrow fibrosis.
Emily HayesMyelofibrosis | March 4, 2024
Prevalence of symptoms was assessed with the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Emily HayesMyelofibrosis | March 4, 2024
The retrospective study evaluated if pacritinib increased PLT counts in the phase III PERSIST-2 and phase II PAC203 studies.
Melissa BadamoMyeloproliferative Neoplasms | December 13, 2023
Tasquinimod inhibited interaction of A9, a protein associated with poor prognosis.
Melissa BadamoMyeloproliferative Neoplasms | December 13, 2023
DT2216 alone was effective, but exhibited a slightly greater cell viability reduction when combined with other therapies.
Blood Cancers Today Staff WritersMyelofibrosis | March 4, 2024
Responses in hemoglobin, white blood cell, and platelet were 75%, 82%, and 74%, respectively, at 24 weeks.
Blood Cancers Today Staff WritersMyelofibrosis | March 4, 2024
Multivariable modeling showed a notable reduction in the risk of GVHD or relapse in the ATG group.
Blood Cancers Today Staff WritersMyelofibrosis | March 4, 2024
Hemoglobin and platelets are correlated with OS, while mutations in ASXL1, EZH2, IDH1/2, U2AF1, and SRSF2 are not.
Patrick DalyPolycythemia Vera | December 13, 2023
Rusfertide quickly induced hematocrit control and maintained improved levels over time in patients with polycythemia vera.
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 13, 2023
Subjectivity of morphological assessment and overlapping pathological features of subtypes can hamper accurate MPN diagnosis.
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 7, 2023
Bomedemstat is an oral lysine-specific demethylase-1 (LSD1) inhibitor clinically active in patients with MPNs.
Emily HayesMyelofibrosis | March 4, 2024
The model could be helpful in understanding fibrotic progression in JAK2V617F mutation–positive MPNs.
Patrick DalyMyelofibrosis | March 4, 2024
The study aimed to address “a substantial unmet need for therapies that alter disease trajectory" in patients with MF.
Blood Cancers Today Staff WritersMyelofibrosis | March 4, 2024
Ruben Mesa, MD, discussed the results at the 65th ASH Annual Meeting and Exposition.
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 13, 2023
Researchers analyzed PV patients allocated to the ropeginterferon alfa-2b arm of the PROUD-PV/CONTINUATION-PV studies.
Blood Cancers Today Staff WritersMyelofibrosis | March 4, 2024
The use of combination therapies including XPO1 inhibitor selinexor is a potentially effective therapeutic strategy in MF.
Patrick DalyMyelofibrosis | March 4, 2024
This is just one finding from a longitudinal analysis of phase III data from the SIMPLIFY-1 and MOMENTUM trials.
Advertisement
Advertisement
Latest News

June 21, 2024